Appeals Court Hears Case on Graphic Warnings on Cigarette Packs
The battle over graphic warning images on cigarette packs resumes Tuesday in a U.S. federal appeals court.
The Obama administration wants cigarette packs to carry shocking images -- such as diseased lungs or a man exhaling smoke through a hole in his windpipe -- in order to discourage potential smokers. Tobacco companies say the measure violates their First Amendment rights, CBS News reported.
A federal judge ruled earlier this year that forcing tobacco companies to place the images on their cigarettes packs violates their constitutional right to free speech. The Obama administration appealed that decision.
The graphic warning labels were supposed to begin appearing on cigarette packs in September. But it's possible the case will go all the way to the Supreme Court and take years to resolve, CBS News reported.
-----
EPA Rejects Petition to Ban 2,4-D Weed Killer
An environmental group's petition to ban the widely used herbicide 2,4-D has been rejected by the U.S. Environmental Protection Agency.
The agency said the petition from the Natural Resources Defense Council did not adequately show that 2,4-D was harmful under the conditions in which it is used, The New York Times reported.
The herbicide, first approved in the late 1940s, is one of the most widely used weed killers in the world. It is used by farmers and is an ingredient in many home lawn-care products.
In its petition, the Natural Resources Defense Council cited studies suggesting that exposure to 2, 4-D could cause problems such as cancer, genetic mutations and hormone disruption, The Times reported.
While some of the studies did suggest that high doses of the herbicide could be harmful, they did not establish lack of safety, the EPA said in its ruling.
-----
FDA Delays Decision on Weight-Loss Drug
U.S. regulators will take another three months to decide whether to approve a new obesity drug called Qnexa, drugmaker Vivus Inc. said Monday.
The Food and Drug Administration was scheduled to make a decision by April 17 but that has been changed to July 17 to give the FDA time to assess a new drug safety plan submitted by Vivus, the Associated Press reported.
The FDA rejected the drug in 2010 over concerns that it can cause heart palpitations and birth defects if taken by pregnant women. Vivus resubmitted the drug for approval and an FDA panel of medical advisers voted in February to recommend approval of the drug.
However, the FDA does not have to follow the advice of its expert panels.
If approved, Qnexa would become the first new prescription weight loss pill to reach the U.S. market in more than a decade, the AP reported.
-----
View the Original article
No comments:
Post a Comment